This narrative review examines how different types of metastasis affect the response to treatments like immune checkpoint inhibitors, anti-angiogenic agents, and targeted therapies for colorectal cancer. The authors looked at existing evidence to see how the location of cancer spread influences patient outcomes.
The main finding indicates that liver metastasis is consistently associated with resistance to immune checkpoint inhibitors. In contrast, lung metastasis demonstrates relatively improved responses to these same treatments. The review highlights these differences in how the body reacts to therapy based on where the cancer has spread.
Because this is a narrative review, it summarizes what other studies have found rather than presenting new data from a single trial. The authors note limitations in the existing evidence that prevent drawing firm conclusions about treatment success rates. Readers should understand that these patterns describe associations seen in past research, not guaranteed results for every patient.
